MX2020003670A - Metodos para tratar infecciones bacterianas. - Google Patents
Metodos para tratar infecciones bacterianas.Info
- Publication number
- MX2020003670A MX2020003670A MX2020003670A MX2020003670A MX2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- methods
- subjects
- transplant
- bone marrow
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567702P | 2017-10-03 | 2017-10-03 | |
| US201862657402P | 2018-04-13 | 2018-04-13 | |
| PCT/US2018/053772 WO2019070591A1 (en) | 2017-10-03 | 2018-10-01 | METHODS OF TREATING BACTERIAL INFECTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003670A true MX2020003670A (es) | 2020-08-03 |
Family
ID=65994826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003670A MX2020003670A (es) | 2017-10-03 | 2018-10-01 | Metodos para tratar infecciones bacterianas. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11376237B2 (https=) |
| EP (1) | EP3691652A4 (https=) |
| JP (1) | JP2020536092A (https=) |
| KR (1) | KR20200066664A (https=) |
| CN (1) | CN111432821A (https=) |
| AU (1) | AU2018345317B2 (https=) |
| BR (1) | BR112020006658A2 (https=) |
| CA (1) | CA3078238A1 (https=) |
| CL (1) | CL2020000892A1 (https=) |
| JO (1) | JOP20200075A1 (https=) |
| MX (1) | MX2020003670A (https=) |
| MY (1) | MY200934A (https=) |
| PH (1) | PH12020550249A1 (https=) |
| SG (1) | SG11202003009QA (https=) |
| TW (2) | TW201922241A (https=) |
| WO (1) | WO2019070591A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11376237B2 (en) | 2017-10-03 | 2022-07-05 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
| EP4313033A4 (en) * | 2021-03-24 | 2025-04-23 | Trustees Of Tufts College | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912363A (zh) | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
| CA2807546C (en) | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN102188395B (zh) | 2011-04-29 | 2012-12-05 | 石药集团中诺药业（石家庄）有限公司 | 一种更稳定的美罗培南注射剂及其制备方法 |
| CN102335136B (zh) | 2011-08-02 | 2013-06-12 | 天津市嵩锐医药科技有限公司 | 一种供注射用美罗培南药物组合物及其制备方法 |
| CN102335137B (zh) | 2011-08-02 | 2013-06-12 | 天津市嵩锐医药科技有限公司 | 一种含美罗培南的药物组合物 |
| CN102525961B (zh) | 2012-01-17 | 2013-02-13 | 山东罗欣药业股份有限公司 | 美罗培南组合物注射用粉针剂 |
| US10561675B2 (en) * | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CN103570718B (zh) | 2012-07-31 | 2016-06-29 | 深圳市海滨制药有限公司 | 一种美罗培南原料药、其制备方法及包含其的药物组合物 |
| RU2675847C2 (ru) | 2013-05-28 | 2018-12-25 | Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми | Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций |
| WO2016172208A1 (en) | 2015-04-24 | 2016-10-27 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| CN108289896B (zh) | 2015-07-09 | 2022-03-01 | 华盛顿大学 | 抗菌药物组合的组合物和使用方法 |
| US9949995B2 (en) | 2015-09-04 | 2018-04-24 | Case Western Reserve University | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors |
| JP7436206B2 (ja) | 2017-01-09 | 2024-02-21 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | 細菌感染症を処置する方法 |
| US11376237B2 (en) * | 2017-10-03 | 2022-07-05 | Melinta Subsidiary Corp. | Methods of treating bacterial infections |
-
2018
- 2018-10-01 US US16/753,288 patent/US11376237B2/en active Active
- 2018-10-01 EP EP18863923.1A patent/EP3691652A4/en active Pending
- 2018-10-01 SG SG11202003009QA patent/SG11202003009QA/en unknown
- 2018-10-01 BR BR112020006658-3A patent/BR112020006658A2/pt not_active Application Discontinuation
- 2018-10-01 WO PCT/US2018/053772 patent/WO2019070591A1/en not_active Ceased
- 2018-10-01 CA CA3078238A patent/CA3078238A1/en active Pending
- 2018-10-01 AU AU2018345317A patent/AU2018345317B2/en not_active Expired - Fee Related
- 2018-10-01 KR KR1020207012784A patent/KR20200066664A/ko not_active Ceased
- 2018-10-01 MX MX2020003670A patent/MX2020003670A/es unknown
- 2018-10-01 JP JP2020519066A patent/JP2020536092A/ja active Pending
- 2018-10-01 MY MYPI2020001141A patent/MY200934A/en unknown
- 2018-10-01 CN CN201880072552.XA patent/CN111432821A/zh active Pending
- 2018-10-01 JO JOP/2020/0075A patent/JOP20200075A1/ar unknown
- 2018-10-02 TW TW107134824A patent/TW201922241A/zh unknown
- 2018-10-02 TW TW112133851A patent/TW202400146A/zh unknown
-
2020
- 2020-04-02 CL CL2020000892A patent/CL2020000892A1/es unknown
- 2020-04-03 PH PH12020550249A patent/PH12020550249A1/en unknown
-
2022
- 2022-05-27 US US17/826,712 patent/US12533342B2/en active Active
-
2025
- 2025-12-16 US US19/421,222 patent/US20260102374A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018345317B2 (en) | 2024-10-24 |
| CA3078238A1 (en) | 2019-04-11 |
| EP3691652A1 (en) | 2020-08-12 |
| US11376237B2 (en) | 2022-07-05 |
| JP2020536092A (ja) | 2020-12-10 |
| US20200297695A1 (en) | 2020-09-24 |
| JOP20200075A1 (ar) | 2020-04-30 |
| AU2018345317A1 (en) | 2020-05-07 |
| PH12020550249A1 (en) | 2021-02-15 |
| KR20200066664A (ko) | 2020-06-10 |
| EP3691652A4 (en) | 2021-07-07 |
| MY200934A (en) | 2024-01-24 |
| US20220288024A1 (en) | 2022-09-15 |
| CN111432821A (zh) | 2020-07-17 |
| CL2020000892A1 (es) | 2020-10-23 |
| BR112020006658A2 (pt) | 2020-09-24 |
| SG11202003009QA (en) | 2020-04-29 |
| WO2019070591A1 (en) | 2019-04-11 |
| US12533342B2 (en) | 2026-01-27 |
| US20260102374A1 (en) | 2026-04-16 |
| TW202400146A (zh) | 2024-01-01 |
| TW201922241A (zh) | 2019-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008677A (es) | Conjugados de camptotecina. | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| CL2022001752A1 (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| EP4599848A3 (en) | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant | |
| MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| CY1125242T1 (el) | Κυτταροκαλλιεργεια | |
| NZ742208A (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| EP4389209A3 (en) | Fecal microbiota composition, for use in reducing treatment-induced inflammation | |
| ES2525137B1 (es) | Agentes para tratar el mieloma múltiple | |
| PH12017501300A1 (en) | Novel iodophor composition and methods of use | |
| WO2018217710A8 (en) | Micro-nanobubble solutions for tissue preservation and generation thereof | |
| WO2018009528A8 (en) | Combination cancer immunotherapies with arginine depletion agents | |
| CL2018001913A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| MX393900B (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| CO2020006907A2 (es) | Péptidos antimicrobianos y métodos para usarlos | |
| CO2018008449A2 (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| CL2018001911A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| CL2019001918A1 (es) | Métodos para tratar infecciones bacterianas. | |
| MX2020003670A (es) | Metodos para tratar infecciones bacterianas. | |
| WO2020072519A8 (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
| MX2024005589A (es) | Combinaciones de lurbinectedina y atezolizumab. | |
| GEAP202215466A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment |